Combined Antidepressant Effect of Acetyl-L-Carnitine and Bupropion against Experimental Animal Model
Abstract
Depression is one of the most common mental diseases characterized by mood disorders affecting around 322 million individuals in the world. Depression is a feeling of inadequacy, dejection, anhedonia, and decreased activity in any action. Previously acetyl-L-carnitine reported beneficial effects on lipid metabolism, neuroprotection, and some types of depression. Therefore, in the present study, we evaluated the combined effect of acetyl-L-carnitine and bupropion against experimental-induced depression. Albino rats were divided into different groups (each group contained six animals). Normal groups received saline (1 mL/kg, i.p.). The standard group received imipramine (20 mg/kg, i.p.). The ALC group received acetyl-L-carnitine (100 mg/kg, i.p.), and the BPR group received bupropion (20 mg/kg, i.p.). T I and T II groups received acetyl-L-carnitine (30 mg/kg, i.p.) + Bupropion (10 mg/kg, i.p.) and acetyl-L-carnitine (80 mg/kg, i.p.) + Bupropion (30 mg/kg, i.p.), respectively. Antidepressant effects were assessed by forced swim test and sucrose preference test. In both models, the combined effect of the drug produced a significant (p < 0.05) antidepressant action as compared to the depression control group. Based on the findings, the combined effect of acetyl-L-carnitine and bupropion had a better therapeutic effect to combat depression as compared to individual treatments.
Keywords:
Depression, Acetyl L carnitine, Bupropion, Forced swim test, Sucrose preference testDOI
https://doi.org/10.25004/IJPSDR.2024.160103References
de Zwart PL, Jeronimus BF, de Jonge P. Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review. Epidemiology and psychiatric sciences. 2019;28:544-62.
Gilbert P. Psychotherapy and Counselling for Depression. 3rd ed. London: Sage; 2007.
UN News. UN health agency reports depression now 'leading cause of disability worldwide. Global Perspective Human Stories. United Nation 2017.
Razzak HA, Harbi A, Ahli S. Depression: Prevalence and Associated Risk Factors in the United Arab Emirates. Oman medical journal. 2019;34:274-82.
Wessa M, Lois G. Brain Functional Effects of Psychopharmacological Treatment in Major Depression: a Focus on Neural Circuitry of Affective Processing. Current neuropharmacology. 2015;13:466-79.
Miller CH, Hamilton JP, Sacchet MD, Gotlib IH. Meta-analysis of Functional Neuroimaging of Major Depressive Disorder in Youth. JAMA Psychiatry. 2015;72:1045-53.
Sarzi-Puttini P, Giorgi V, Di Lascio S, Fornasari D. Acetyl-L-carnitine in chronic pain: A narrative review. Pharmacological research. 2021;173:105874.
Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biological psychiatry. 1998;43:315-9.
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. A review of current evidence for acetyl-l-carnitine in the treatment of depression. Journal of psychiatric research. 2014;53:30-7.
Mahar I, Bambico FR, Mechawar N, Nobrega JN. Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neuroscience & Biobehavioral Reviews. 2014;38:173-92.
Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathé AA, Pittaluga A, Lionetto L, et al. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:4804-9.
Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Therapeutic advances in psychopharmacology. 2016;6:99-144.
Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Primary care companion to the Journal of clinical psychiatry. 2004;6:159-66.
Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1-11.
Chen F, Madsen TM, Wegener G, Nyengaard JR. Imipramine treatment increases the number of hippocampal synapses and neurons in a genetic animal model of depression. Hippocampus. 2010;20:1376-84.
Dhir A, Kulkarni SK. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol. 2007;568:177-85.
Krishnan V, Nestler EJ. Animal models of depression: molecular perspectives. Current topics in behavioral neurosciences. 2011;7:121-47.
Frye CA, Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Hormones and behavior. 2002;41:306-15.
Porsolt RD, Deniel M, Jalfre M. Forced swimming in rats: hypothermia, immobility and the effects of imipramine. European journal of pharmacology. 1979;57:431-6.
Drossopoulou G, Antoniou K, Kitraki E, Papathanasiou G, Papalexi E, Dalla C, Papadopoulou-Daifoti Z. Sex differences in behavioral, neurochemical and neuroendocrine effects induced by the forced swim test in rats. Neuroscience. 2004;126:849-57.
Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology. 1987;93:358-64.
Dalili MN, Penton-Voak IS, Harmer CJ, Munafò MR. Meta-analysis of emotion recognition deficits in major depressive disorder. Psychological medicine. 2015;45:1135-44.
Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metabolic brain disease. 2013;28:193-9.
Alhasaniah AH. l-carnitine: Nutrition, pathology, and health benefits. Saudi journal of biological sciences. 2023;30:103555.
Clapper JR, Athanacio J, Wittmer C, Griffin PS, D'Souza L, Parkes DG, Roth JD. Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. European journal of pharmacology. 2013;698:292-8.
Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. Journal of psychiatric practice. 2004;10:239-48.
Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neuroscience and biobehavioral reviews. 2005;29:571-625.
WHO. Obesity and overweight. 2020.
Smeland OB, Meisingset TW, Borges K, Sonnewald U. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochemistry international. 2012;61:100-7.
Hoffman KL. 2 - What can animal models tell us about depressive disorders? In: Hoffman KL, editor. Modeling Neuropsychiatric Disorders in Laboratory Animals: Woodhead Publishing; 2016. p. 35-86.
Markov DD. Sucrose Preference Test as a Measure of Anhedonic Behavior in a Chronic Unpredictable Mild Stress Model of Depression: Outstanding Issues. Brain sciences. 2022;12.
Matthews K, Forbes N, Reid IC. Sucrose consumption as an hedonic measure following chronic unpredictable mild stress. Physiology & behavior. 1995;57:241-8.
Klein DF. Endogenomorphic depression. A conceptual and terminological revision. Archives of general psychiatry. 1974;31:447-54.
Published
Abstract Display: 534 
PDF Downloads: 428 
